Molecular analyses, mainly focusing on genetic rearrangements in genes such as ALK, ROS1, RET, and NTRK [135], have become standard practices in patients with advanced NSCLC—immunohistochemistry (IHC) functions as the primary screening method, valued for its ease of implementation and interpretation. This evidence concerns the gene ALK and non-small cell lung carcinoma.